Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • China rebukes west over military moves after close call in Taiwan Strait
    • India blames train crash on signal failure as death toll nears 300
    • Three Israeli soldiers shot dead on Egyptian border
    • Train crash in India kills more than 260 people
    • Erdoğan signals economic shift for Turkey as he revamps cabinet
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Boiler makers up in arms over UK heat pump targets
      • UBS considers delaying results after Credit Suisse rescue deal
      • AstraZeneca defies geopolitics to bet on China
      • ‘This is not just channel Farage’: GB News boss positions his station as ‘mainstream’
      • Asda’s owners recycle proceeds of earlier deal to fund EG takeover
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Saudi Arabia seeks to boost oil price with output cut of 1mn barrels a day
      • Saudi Arabia’s ‘prickly prince’ of oil bristles as crude price slides
      • Japan inflation will drive savers back to the stock market, says exchange chief
      • Handful of tech stocks drive diverging measures of S&P 500 performance
      • Orlen: is Poland’s energy giant a tool of the government?
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Europe’s new success stories are built on high luxury, not high tech
      • The dismal truth about email
      • The frictionless life goes on
      • Management 101: don’t drain a reservoir to find your phone
      • Ukraine’s rapid reconstruction will be in Europe’s own interest
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • The dismal truth about email
      • Can a virtual PA turbocharge your career?
      • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Why motorcycle gangs will end with a whimper, not a rev
      • Cristiano Ronaldo vs Lionel Messi: who was the greatest footballer?
      • Sci-fi writer Ted Chiang: ‘The machines we have now are not conscious’
      • The American luxury lifestyle brand storming the Cotswolds
      • Trump or not, US meltdown could be inevitable
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Dementia

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Sunday, 14 May, 2023
      Japan pushes for strong pledges on tackling dementia from G7 allies

      Alzheimer’s advocates call for ambitious declaration to match the scope of commitments made 10 years ago

    • Monday, 8 May, 2023
      Two Alzheimer’s drugs offer hope to patients after decades of waiting

      In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

    • Wednesday, 3 May, 2023
      Eli Lilly & Co
      Eli Lilly to seek US approval after Alzheimer’s drug trial success

      Clinical study results could boost patient access to new class of treatment

    • Wednesday, 19 April, 2023
      ReviewFT Books Essay
      Alternative realities: caring for people with dementia

      With an ageing global population, cases of the disease continue to drastically rise. Two timely and insightful books offer help on how to support the millions of new patients

    • Monday, 20 February, 2023
      OutlookPatti Waldmeir
      How banks may catch signs of dementia before the doctors do

      Money problems experienced by elderly customers can be red flags for families and institutions alike

    • Wednesday, 11 January, 2023
      Anjana Ahuja
      New Alzheimer’s drug straddles uneasy gulf between help and harm

      For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

    • Thursday, 29 December, 2022
      Biogen Inc
      Congress faults US regulator’s approval of Biogen Alzheimer’s drug

      Committees cite inappropriate collaboration between FDA and drugmaker

    • Friday, 2 December, 2022
      Pharmaceuticals sector
      Swedish scientist behind Alzheimer’s drug has big ambitions

      Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

    • Friday, 2 December, 2022
      The editorial board
      A glimmer of hope in treating Alzheimer’s disease

      Dementia drug development, diagnostics and delivery still require much more investment

    • Wednesday, 30 November, 2022
      Eisai says Alzheimer’s drug did not cause deaths of trial patients

      Japanese company refuses to rule out possibility treatment contributed to brain bleeds

    • Tuesday, 29 November, 2022
      Eisai Co Ltd
      Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

      Shares fall 11% following two patient deaths in trials of lecanemab

    • Monday, 28 November, 2022
      LexDrugs research
      Dementia/Biogen: causal controversy means investors must take a stance Premium content

      The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

    • Monday, 14 November, 2022
      Roche Holding AG
      Roche late-stage Alzheimer’s trials end in failure

      Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    • Sunday, 13 November, 2022
      Insurance
      AI is giving insurers godlike powers, says Sompo chief

      Access to large data sets means predictions are far more accurate in reducing risk

    • Monday, 24 October, 2022
      Special ReportFT Health: Communicable Diseases
      Evidence builds of viruses’ role in Alzheimer’s disease

      Researchers focus on pathogens including Covid, herpes and Epstein-Barr virus

    • Wednesday, 28 September, 2022
      Pharmaceuticals sector
      Biogen and Eisai shares surge after Alzheimer’s drug trial success

      Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

    • Friday, 23 September, 2022
      Health sector
      Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

      Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts

    • Monday, 22 August, 2022
      Medical science
      Electrical brain stimulation improves memory in elderly, research finds

      Study could be used to help boost cognitive performance of people developing Alzheimer’s disease

    • Wednesday, 17 August, 2022
      Coronavirus
      Covid can cause brain disorders two years after infection, study shows

      Long-term effects are generally less in children, although infection doubles risk of epilepsy

    • Wednesday, 18 May, 2022
      Coronavirus
      How can Covid-19 affect the human brain?

      Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting

    • Sunday, 17 April, 2022
      Anjana Ahuja
      Hasty approval for Alzheimer’s drug offers a cautionary tale

      FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say

    • Friday, 8 April, 2022
      News in-depthPharmaceuticals sector
      US imposes strict curbs on contentious Biogen Alzheimer’s treatment

      Agency that controls spending by government health schemes will not fund drug for most patients

    • Thursday, 13 January, 2022
      ReviewNon-Fiction
      What I Wish People Knew About Dementia — uplifting depiction

      Practical and reassuring tale written with eloquence and insight about a disease which for years was presumed to rob sufferers of sentience

    • Wednesday, 20 October, 2021
      Biogen Inc
      Biogen sells just $300,000 worth of contentious Alzheimer’s drug

      Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m

    • Wednesday, 1 September, 2021
      Scientists warn that Covid will accelerate ‘dementia pandemic’

      Experts point to mounting evidence that the virus can cause long-term brain damage in some patients

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In